PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

计划入组 42 人 · 首次发布于 2020 年 11 月 12 日

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

计划入组 6 人 · 首次发布于 2020 年 9 月 25 日

GlyT-1 Inhibitor Treatment for Refractory Schizophrenia

计划入组 40 人 · 首次发布于 2010 年 12 月 1 日

11-beta HSD-1 inhibitor (Cushing Syndrome)

11-beta hydroxysteroid dehydrogenase-1 inhibitors (Orchid)

11-beta hydroxysteroid dehydrogenase-1 inhibitors (AstraZeneca)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Sparrow Pharmaceuticals Secures $95 Million Series B to Advance Novel Diabetes Treatment Targeting Elevated Cortisol

Clofutriben Granted FDA Orphan Drug Designation for Endogenous Cushing Syndrome

Sparrow Pharmaceuticals' Clofutriben Completes Phase 2 Trial and Receives FDA Orphan Drug Designation for Cushing's Syndrome